Title
Is VEGF a key target of cotinine and other potential therapies against Alzheimer disease?
Date Issued
01 January 2017
Access level
metadata only access
Resource Type
review
Author(s)
Pontificia Universidad Javeriana
Publisher(s)
Bentham Science Publishers B.V.
Abstract
Background: The vascular endothelial growth factor (VEGF) is a neuroprotective cytokine that promotes neurogenesis and angiogenesis in the brain. In animal models, it has been shown that environmental enrichment and exercise, two non-pharmacological interventions that are beneficial decreasing the progression of Alzheimer disease (AD) and depressive-like behavior, enhance hippocampal VEGF expression and neurogenesis. Furthermore, the stimulation of VEGF expression promotes neurotransmission and synaptic plasticity processes such as neurogenesis. It is thought that these VEGF actions in the brain, may underly its beneficial therapeutic effects against psychiatric and other neurological conditions. Conclusion: In this review, evidence linking VEGF deficit with the development of AD as well as the potential role of VEGF signaling as a therapeutic target for cotinine and other interventions in neurodegenerative conditions are discussed.
Start page
1155
End page
1163
Volume
14
Issue
11
Language
English
OCDE Knowledge area
Neurología clínica
Subjects
Scopus EID
2-s2.0-85030086523
PubMed ID
Source
Current Alzheimer Research
ISSN of the container
15672050
Sponsor(s)
aFacultad de Cs de la Salud, Universidad San Sebastian, Lientur 1457, Concepción, 4030000, Chile.bResearch and Development, Bay Pines VA Healthcare System, Bay Pines, FL, USA;cDepartamento de Nutrición y Bioquímica, Facul-tad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia; dCenter for Biomedical Research, Universi-dad Autónoma de Chile, Carlos Antúnez 1920, Providencia, Santiago, Chile; eInstitute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, 2-4 Bolshaya Pirogovskaya St., 119991 Moscow, Russia; fGALLY International Biomedical Research Consulting LLC San Antonio, TX, USA ; gSchool of Health Science and Healthcare Administration, University of Atlanta, Johns Creek, Georgia, 30097, USA; hInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia
This work was performed with resources from the University San Sebastian, Chile and the Grant Fondecyt regular 1150194 (to VE). G. Aliev work is supported by the Russian Scientific Foundation (www.rscf.ru, Grant No 14-23-00160 for 2014-2016: Directed design, synthesis, and study of biological activity of multi-target compounds as innovative drugs for treatment of neurodegenerative diseases) and “GALLY” International Biomedical Research Consulting LLC, San Antonio, TX, USA. GEB work is supported by Pontificia Universidad Javeriana.
Sources of information:
Directorio de Producción Científica
Scopus